-
Uncategorized2 months ago
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
-
Uncategorized2 months ago
Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025
Kailera Therapeutics—one of the biggest money-raisers of 2025—is now seeking to go public as it seeks further funding to push its obesity portfolio through the clinic.Read...
-
Uncategorized2 months ago
StockWatch: Wave Plummets 50% on Obesity Data
Disappointed investors punished Wave Life Sciences (NASDAQ: WVE), causing its shares to lose roughly half their value on Thursday after the RNA-based drug developer reported mixed...
-
Uncategorized2 months ago
Engineering macrophage-targeted trispecific immune cell engagers for tumor immunotherapy
Nature Biotechnology, Published online: 30 March 2026; doi:10.1038/s41587-026-03104-5 Immune cell engagers (ICEs) have emerged as a promising strategy for cancer immunotherapy, but their efficacy in solid...
-
Uncategorized2 months ago
Kailera plans IPO for Phase 3 obesity drug from Hengrui
Kailera plans IPO for Phase 3 obesity drug from Hengrui
-
Uncategorized2 months agoSTAT+: AI drug developer Insilico Medicine and Lilly ink commercialization deal worth up to $2.75 billion
Alex Zhavoronkov, CEO of Insilico Medicine, can’t stop complimenting Eli Lilly. “Lilly is better in AI than Insilico, and no other company is better in AI...
-
Uncategorized2 months ago
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
#ACC26: Merck leans toward lower Winrevair dose in Phase 3 trial for rare form of heart failure
-
Uncategorized3 months ago
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
-
Uncategorized3 months ago
#AAD26: Tanabe’s Phase 3 win for drug targeting rare diseases that cause pain upon light exposure
Tanabe Pharma unveiled positive data from a Phase 3 trial of its oral drug for a pair of rare diseases, its first major clinical milestone after...
-
Endpoints News3 months ago
A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and more
Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below for...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
